CPIX
Income statement / Annual
Last year (2024), Cumberland Pharmaceuticals Inc.'s total revenue was $37.87 M,
a decrease of 4.26% from the previous year.
In 2024, Cumberland Pharmaceuticals Inc.'s net income was -$6.48 M.
See Cumberland Pharmaceuticals Inc.,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
FY-2015
|
| Period Ended |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
12/31/2015 |
| Operating Revenue |
$37.87 M |
$39.55 M |
$42.01 M |
$35.99 M |
$37.44 M |
$34.39 M |
$40.74 M |
$41.15 M |
$33.03 M |
$33.52 M |
| Cost of Revenue |
$6.59 M
|
$6.07 M
|
$9.12 M
|
$8.81 M
|
$8.65 M
|
$7.42 M
|
$7.38 M
|
$7.37 M
|
$5.96 M
|
$4.97 M
|
| Gross Profit |
$26.38 M
|
$33.49 M
|
$32.89 M
|
$27.17 M
|
$28.79 M
|
$26.97 M
|
$33.36 M
|
$33.78 M
|
$27.07 M
|
$28.55 M
|
| Gross Profit Ratio |
0.7
|
0.85
|
0.78
|
0.76
|
0.77
|
0.78
|
0.82
|
0.82
|
0.82
|
0.85
|
| Research and Development Expenses |
$4.82 M
|
$5.83 M
|
$6.69 M
|
$5.68 M
|
$5.77 M
|
$6.87 M
|
$7.32 M
|
$3.90 M
|
$3.19 M
|
$3.85 M
|
| General & Administrative Expenses |
$11.13 M
|
$10.65 M
|
$10.18 M
|
$9.78 M
|
$10.20 M
|
$9.97 M
|
$10.41 M
|
$10.03 M
|
$8.56 M
|
$7.61 M
|
| Selling & Marketing Expenses |
$17.02 M
|
$18.45 M
|
$16.66 M
|
$15.02 M
|
$14.77 M
|
$15.28 M
|
$20.26 M
|
$21.49 M
|
$14.55 M
|
$13.99 M
|
| Selling, General & Administrative Expenses |
$28.15 M
|
$29.10 M
|
$26.84 M
|
$24.80 M
|
$24.96 M
|
$25.25 M
|
$30.66 M
|
$31.52 M
|
$23.12 M
|
$21.60 M
|
| Other Expenses |
$0.00
|
$8.10 M
|
$5.07 M
|
$4.37 M
|
$4.43 M
|
$4.13 M
|
$2.77 M
|
$2.44 M
|
$2.19 M
|
$1.99 M
|
| Operating Expenses |
$33.48 M
|
$43.04 M
|
$38.60 M
|
$34.85 M
|
$35.17 M
|
$36.26 M
|
$40.75 M
|
$37.86 M
|
$28.50 M
|
$27.44 M
|
| Cost And Expenses |
-$44.97 M
|
$49.11 M
|
$47.72 M
|
$43.66 M
|
$43.82 M
|
$43.68 M
|
$48.13 M
|
$45.23 M
|
$34.46 M
|
$32.41 M
|
| Interest Income |
$334.44 K
|
$286.85 K
|
$98.41 K
|
$26.08 K
|
$75.35 K
|
$243.36 K
|
$564.48 K
|
$299.33 K
|
$204.66 K
|
$209.18 K
|
| Interest Expense |
$605.51 K
|
$667.86 K
|
$586.00 K
|
$98.03 K
|
$263.63 K
|
$246.19 K
|
$195.85 K
|
$92.90 K
|
$106.39 K
|
$73.86 K
|
| Depreciation & Amortization |
$6.04 M
|
$5.77 M
|
$5.33 M
|
$4.61 M
|
$4.75 M
|
$4.40 M
|
$2.98 M
|
$2.65 M
|
$2.40 M
|
$2.25 M
|
| EBITDA |
$182.42 K |
$153.32 K |
$332.92 K |
-$857.83 K |
-$1.56 M |
-$4.64 M |
-$8.19 M |
-$1.13 M |
$1.17 M |
$3.57 M |
| EBITDA Ratio |
0
|
0
|
0.01
|
-0.02
|
-0.04
|
-0.13
|
-0.2
|
-0.03
|
0.04
|
0.11
|
| Operating Income Ratio |
-0.19
|
-0.16
|
-0.14
|
-0.21
|
-0.17
|
-0.27
|
-0.18
|
-0.1
|
-0.04
|
-0.03
|
| Total Other Income/Expenses Net |
$635.00 K
|
-$74.18 K
|
$123.74 K
|
$2.12 M
|
-$188.28 K
|
-$2.82 K
|
$368.64 K
|
$206.42 K
|
$98.27 K
|
$135.33 K
|
| Income Before Tax |
-$6.47 M
|
-$6.28 M
|
-$5.58 M
|
-$5.56 M
|
-$6.57 M
|
-$9.29 M
|
-$7.02 M
|
-$3.87 M
|
-$1.33 M
|
$1.25 M
|
| Income Before Tax Ratio |
-0.17
|
-0.16
|
-0.13
|
-0.15
|
-0.18
|
-0.27
|
-0.17
|
-0.09
|
-0.04
|
0.04
|
| Income Tax Expense |
-$22.67 K
|
$45.77 K
|
$68.85 K
|
$34.89 K
|
$55.90 K
|
-$79.32 K
|
$16.64 K
|
$4.17 M
|
-$330.92 K
|
$575.83 K
|
| Net Income |
-$6.48 M
|
-$6.28 M
|
-$5.65 M
|
-$5.60 M
|
-$6.63 M
|
-$9.21 M
|
-$6.96 M
|
-$7.98 M
|
-$944.68 K
|
$731.35 K
|
| Net Income Ratio |
-0.17
|
-0.16
|
-0.13
|
-0.16
|
-0.18
|
-0.27
|
-0.17
|
-0.19
|
-0.03
|
0.02
|
| EPS |
-0.46 |
-0.44 |
-0.39 |
-0.38 |
-0.44 |
-0.6 |
-0.45 |
-0.5 |
-0.06 |
0.04 |
| EPS Diluted |
-0.46 |
-0.44 |
-0.39 |
-0.38 |
-0.44 |
-0.6 |
-0.45 |
-0.5 |
-0.0582 |
0.04 |
| Weighted Average Shares Out |
$14.06 M
|
$14.30 M
|
$14.56 M
|
$14.90 M
|
$15.16 M
|
$15.40 M
|
$15.57 M
|
$15.91 M
|
$15.74 M
|
$16.72 M
|
| Weighted Average Shares Out Diluted |
$14.06 M
|
$14.30 M
|
$14.56 M
|
$14.90 M
|
$15.16 M
|
$15.40 M
|
$15.61 M
|
$15.91 M
|
$16.24 M
|
$17.09 M
|
| Link |
|
|
|
|
|
|
|
|
|
|
